Verdad Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
RI
PAI
Verdad Advisers's ACAD Position: Q2 2026 in Review
Verdad Advisers increased its Acadia Pharmaceuticals (ACAD) stake by 21% in Q2 2026, buying an estimated $315K and bringing the position to 82,629 shares worth $2.09M. The position accounts for 2% of the portfolio, ranked #3.
Verdad Advisers first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- Verdad Advisers held 82,629 shares of Acadia Pharmaceuticals worth $2.09M as of Q2 2026.
- Verdad Advisers bought 14,339 Acadia Pharmaceuticals shares in Q2 2026, an estimated $315K.
- Acadia Pharmaceuticals made up 2% of Verdad Advisers's portfolio in Q2 2026, its #3 holding.
- Verdad Advisers first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
- 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.